The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Open accessAbstract
SUMMARY Background: MET signaling is a key driver of papillary renal cell carcinoma (PRCC). Given that there is no optimal therapy for metastatic PRCC, we sought to compare an existing standard (sunitinib) to MET kinase inhibitors. Methods: We conducted a randomized, open-label, phase II trial involving patients with metastatic PRCC who had received up to one prior therapy (excluding vascular endothelial growth factor-directed agents). Patients were assigned to receive sunitinib, cabozantinib, crizotinib or savolitinib, with stratification by receipt of prior therapy and PRCC subtype. Progression-free survival (PFS) was the primary endpoint. With 41 eligible patients per arm, there was 85% power to detect a 75% improvement in median PFS in each experimental arm compared to sunitinib, employing a one-sided alpha of 0.10 for each test. Findings: Overall, 152 patients were enrolled. Enrollment to savolitinib (N=29) and crizotinib (N=28) arms was halted after a pre-specified futility analysis; planned accrual was completed for both sunitinib (N=46) and cabozantinib (n=44) arms. PFS was longer with cabozantinib versus sunitinib (9.0 months vs. 5.6 months; hazard ratio for progression or death, 0.60; 95% CI 0.37–0.97, P=0.019 [1-sided]). Response rate for cabozantinib was 23% versus 4% for sunitinib (2-sided P=0.010). Savolitinib and crizotinib did not improve PFS relative to sunitinib. Grade 3 or 4 adverse events occurred in 69%, 74%, 37% and 39% of patients receiving sunitinib, cabozantinib, crizotinib and savolitinib, respectively; one grade 5 thromboembolic event was seen with cabozantinib. Interpretation: Cabozantinib resulted in significantly longer PFS when compared to sunitinib in patients with metastatic PRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.029 · Cited by 3,086
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., Hes, O., Moch, H., Montironi, R., Tickoo, S. K., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318299f2d1 · Cited by 1,047
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3383 · Cited by 463
Self-citationArmstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 426
Self-citationChoueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.012 · Cited by 398
Self-citationTannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Cited by
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bedke, J., Capitanio, U., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.03.006 · Cited by 1,508
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 667
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.537 · Cited by 369
Kidney cancer models for pre-clinical drug discovery: challenges and opportunities
Pohl, L., Friedhoff, J., Jurcic, C., Teroerde, M., Schindler, I., Strepi, K., Schneider, F., Kaczorowski, A., Hohenfellner, M., Duensing, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889686 · Cited by 5
Metadata
- Authors
- Pal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., Adeniran, A., Narayan, V., Bjarnason, G. A., Vaishampayan, U., Alva, A., Zhang, T., Cole, S., Plets, M., Wright, J., & Lara, P. N.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 397
- Issue
- 10275
- Pages
- 695-703
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3129780093
- Cited by
- 287
- References
- 24
- FWCI
- 28.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00152-5
- The paper
- Pal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., Adeniran, A., Narayan, V., Bjarnason, G. A., Vaishampayan, U., Alva, A., Zhang, T., Cole, S., Plets, M., Wright, J., & Lara, P. N. (2021). A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)00152-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.